Trends in treatment of cT1 penile cancer: Analysis of the National Cancer Database.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
08 2020
Historique:
received: 02 01 2020
revised: 03 03 2020
accepted: 06 04 2020
pubmed: 16 5 2020
medline: 30 4 2021
entrez: 16 5 2020
Statut: ppublish

Résumé

To characterize the treatment trends and outcomes in clinical stage T1 penile cancer using the National Cancer Database (NCDB). The National Cancer Database was queried for all men with cT1 penile cancer from 2004 to 2015. Patients were categorized as cT1a or cT1b. Treatment was categorized as no treatment, local therapy (including penile sparing therapies), partial penectomy, or radical penectomy. Trends in treatment were analyzed over time and in correlation with stage and demographic variables. Stage and treatment type were evaluated in respect to pathological outcomes and survival. A total of 2,484 men were identified with cT1 penile cancer, 90.1% of which had cT1a disease. The most common treatments were local therapy for cT1a and partial penectomy for cT1b. Over the time period studied, use of local therapy decreased while use of partial or radical penectomy increased. Patients treated at low volume facilities were more likely to undergo no treatment (8.0% vs. 6.5% in high volume) or local therapy (49.9% vs. 41.5% in high volume, P < 0.001). Local therapy was associated with increased risk of positive margin (odds ratio 4.7, P < 0.001) and positive margin was associated with a trend toward decreased overall survival (P = 0.07). In the past decade, there has been decreased use of local therapy and increased use of partial or radical penectomy in cT1 penile cancer. Men treated at low volume facilities are more likely to be treated with local therapy which is associated with increased rates of positive margins and may also be associated with a trend toward decreased overall survival. Centralization of care in T1 penile cancer may lead to improved outcomes.

Identifiants

pubmed: 32409201
pii: S1078-1439(20)30138-1
doi: 10.1016/j.urolonc.2020.04.013
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

688.e1-688.e9

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Allison May (A)

Division of Urology, Department of Surgery, Saint Louis University, St Louis, MO.

Parth Joshi (P)

Saint Louis University School of Medicine, St Louis, MO.

Facundo Davaro (F)

Division of Urology, Department of Surgery, Saint Louis University, St Louis, MO.

Syed Johar Raza (SJ)

Division of Urology, Department of Surgery, Saint Louis University, St Louis, MO.

Sameer Siddiqui (S)

Division of Urology, Department of Surgery, Saint Louis University, St Louis, MO.

Zachary Hamilton (Z)

Division of Urology, Department of Surgery, Saint Louis University, St Louis, MO. Electronic address: zachary.hamilton@health.slu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH